Do "so-called" normal growth hormone concentrations (2-5 micrograms/l) indicate cure in acromegaly?
- PMID: 7750902
- DOI: 10.1055/s-2007-979936
Do "so-called" normal growth hormone concentrations (2-5 micrograms/l) indicate cure in acromegaly?
Abstract
The study was undertaken to determine whether acromegalic patients with mean growth hormone (GH) concentrations of 2-5 micrograms/l have biochemically active disease following pituitary surgery or radiotherapy. 22 patients with acromegaly, 22 post surgery, 19 post radiotherapy had GH concentrations estimated during: (i) an oral glucose tolerance test (OGTT), (ii) a standard TRH test and (iii) 20 minute sampling for 8 hours. IGF-1 concentrations were measured. 6 normal subjects were also studied. Patients were divided into 3 groups on the basis of their mean GH concentration during the 8 hour sampling, > 5 micrograms/l, 2-5 micrograms/l, < 2 micrograms/l. Patients with mean GH concentrations of 2-5 micrograms/l (n = 6) had biochemically active disease: all had inadequate suppression of GH after OGTT, 5 had elevated IGF-1 concentrations, 4 had a paradoxical response to TRH. Patients with mean GH concentrations > 5 micrograms/l (n = 6) all had inadequate suppression after OGTT, 5 of 6 had increased IGF-1 concentrations, and 5 had abnormal responses to TRH. Of patients with mean GH concentrations < 2 micrograms/l (n = 10), 2 had elevated IGF-1 levels, 5 had abnormal responses to TRH and 4 inadequate GH suppression after OGTT. GH pulse number was similar in the three groups and GH pulse amplitude was significantly higher in those with GH > 5 micrograms/l compared to the other groups. In conclusion patients with GH concentrations of 2-5 micrograms/l have biochemically active disease and should be considered for further therapy after hypophysectomy.
Similar articles
-
Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity.Horm Metab Res. 2010 Jan;42(1):50-5. doi: 10.1055/s-0029-1239522. Epub 2009 Oct 1. Horm Metab Res. 2010. PMID: 19798623
-
Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly.Clin Endocrinol (Oxf). 2006 Aug;65(2):250-6. doi: 10.1111/j.1365-2265.2006.02584.x. Clin Endocrinol (Oxf). 2006. PMID: 16886969
-
Insulin-like growth factor binding protein-3 levels during early and late follow-up after surgery in acromegalic patients.Exp Clin Endocrinol Diabetes. 1998;106(2):130-4. doi: 10.1055/s-0029-1211964. Exp Clin Endocrinol Diabetes. 1998. PMID: 9628244
-
[Discrepancy between IGF-1 and GH during 75 g oral glucose tolerance test measures to acromegaly screening in a patient with macroprolactinoma--case report and literature review].Arq Bras Endocrinol Metabol. 2007 Apr;51(3):494-9. doi: 10.1590/s0004-27302007000300020. Arq Bras Endocrinol Metabol. 2007. PMID: 17546251 Review. Portuguese.
-
How are growth hormone and insulin-like growth factor-1 reported as markers for drug effectiveness in clinical acromegaly research? A comprehensive methodologic review.Pituitary. 2018 Jun;21(3):310-322. doi: 10.1007/s11102-018-0884-4. Pituitary. 2018. PMID: 29605877 Free PMC article. Review.
Cited by
-
Treatment options in acromegaly. Benefits and costs.Pharmacoeconomics. 1996 Nov;10(5):453-9. doi: 10.2165/00019053-199610050-00002. Pharmacoeconomics. 1996. PMID: 10163627 Review. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous